STAT+: After FDA nod, Better Therapeutics races to boost dwindling cash

You’re reading the web edition of STAT Health Tech, our guide to how tech is transforming the life sciences. Sign up to get this newsletter delivered in your inbox every Tuesday and Thursday. The latest on GSK’s AI research, MyChart message billing, & new role for UCSF digital health lead

After FDA nod, Better Therapeutics races to boost dwindling cash

Better Therapeutics has cleared one hurdle: The Food and Drug Administration last week authorized the company to market AspyreRx, its prescription app which uses CBT to treat type 2 diabetes. Better now needs money, and fast. The public company recently raised $6.5 million in a stock sale to supplement its existing reserves, but it’s on the hunt for a medical device or pharmaceutical company partner that can provide the capital needed to fuel commercialization. CEO Frank Karbe told me the company hopes to have a deal in place by the end of the year.

Continue to STAT+ to read the full story…